Rebif news blow against Merck KGaA

Merck KgaA has suffered a triple whammy in the last couple of days: First, Citibank and WestLB downgraded the company's stock. Then came news of a study showing that its MS drug Rebif performs no better than Teva Pharmaceuticals' Copaxone.

Meanwhile, some Israeli scientists have ID'd the genes that predict a positive response to Copaxone, opening the way for personalized treatment using the drug. Does that make it a quadruple whammy?

- see this Weizmann Institute of Science report on the Copaxone genes
- read about the market's response to Merck KGaA news

Related Articles:
Bayer outbids Merck KGaA for Schering. Report
Merck KGaA buying control of Serono. Report
Teva launches pivotal MS drug study. Report

Read more on: Merck KGaA | Teva

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.